Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 226

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 226
---
 development of our product candidates. Our present and future funding requirements and timing and amount of our operating expenditures, both in the near- and long-term, depend on many factors, including, but not limited to:

| • | the scope, progress, results and costs of researching and developing our GH001 and GH002 product candidates, additional mebufotenin delivery approaches and the medical devices required to deliver these therapies for our initial 
 and any additional indications, as well as other product candidates we may develop;                                                                                                                                                 |

| • | the timing and uncertainty of, and the costs involved in, obtaining marketing approvals for our GH001 and GH002 product candidates including the medical devices required to deliver these therapies for our initial and any 
 additional indications, and other product candidates we may develop and pursue;                                                                                                                                              |

| • | the duration of the clinical hold on the study we proposed in our IND for GH001, including the progression of, and associated costs from, any nonclinical programs and any other work necessary to lift the clinical hold, as well as 
 discussions with the FDA and the outcomes and resolution of such discussions;                                                                                                                                                         |

| • | the number of future product candidates that we may pursue and their development requirements; |

| • | the number of jurisdictions in which we plan to seek regulatory approvals; |

| • | if approved, the costs of commercialization activities for GH001 and GH002 for any approved indications, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any 
 future collaborators, including the costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities;                                                                                         |

| • | subject to receipt of regulatory approval, revenue, if any, received from commercial sales of GH001 and GH002 and the respective medical devices for any approved indications or any other product candidates; |

| • | the extent to which we may in-license or acquire rights to other products, product candidates, medical devices or technologies; |

| • | our headcount growth and associated costs as we expand our research and development, increase our office space, and establish a commercial infrastructure; |

| • | the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property-related claims; |

| • | the effect of competing product and market developments; and |

| • | the ongoing costs of operating as a public company. |

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs